P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 1, 2012, Pages 53-61

  Brown, Sarah M ^a   Campbell, Scott D ^b   Crafford, Amanda ^b   Regina, Karen J ^b   Holtzman, Michael J ^a   Kharasch, Evan D ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DRUG METABOLITE; GLYCOPROTEIN P; NORBUPRENORPHINE; NORBUPRENORPHINE 3 GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BREATHING RATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS; ANIMALS; BRAIN; BUPRENORPHINE; CELL LINE; DOGS; HUMANS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PAIN MEASUREMENT;

EID: 84866307024     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193433     Document Type: Article

References (53)

1. Abbott NJ (2005) Physiology of the blood-brain barrier and its consequences for drug transport to the brain. Int Congress Ser 1277:3-18.
2. Aceto MD, McKean DB, and Pearl J (1969) Effects of opiates and opiate antagonists on the Straub tail reaction in mice. Br J Pharmacol 36:225-239.
3. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, and Miller DS (2006) In vivo activation of human pregnane X receptor tightens the bloodbrain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70:1212-1219. (Pubitemid 44435972)
4. Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, and Scheper RJ (2010) Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 65:1672-1680.
5. Bilbey DL, Salem H, and Grossman MH (1960) The anatomical basis of the straub phenomenon. Br J Pharmacol Chemother 15:540-543.
6. Boulton DW, DeVane CL, Liston HL, and Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163-169. (Pubitemid 34595435)
7. Brown SM, Holtzman M, Kim T, and Kharasch ED (2011) Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115:1251-1260.
8. Bruce RD and Altice FL (2006) Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20:783-784. (Pubitemid 43884310)
9. Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, et al. (2009) Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 105:234-239.
10. Cowan A, Lewis JW, and Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545. (Pubitemid 8149539)
11. Dagenais C, Graff CL, and Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276. (Pubitemid 38112757)
12. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174. (Pubitemid 40023528)
13. Engelhardt B (2011) Neuroscience. Blood-brain barrier differentiation. Science 334:1652-1653.
14. Fan J, Brown SM, Tu Z, and Kharasch ED (2011) Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide. Bioconjug Chem 22:752-758.
15. Ge S and Pachter JS (2006) Isolation and culture of microvascular endothelial cells from murine spinal cord. J Neuroimmunol 177:209-214. (Pubitemid 44108240)
16. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665. (Pubitemid 38241451)
17. Hamabe W, Maeda T, Fukazawa Y, Kumamoto K, Shang LQ, Yamamoto A, Yamamoto C, Tokuyama S, and Kishioka S (2006) P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav 85:629-636. (Pubitemid 46097074)
18. Hassan HE, Myers AL, Coop A, and Eddington ND (2009) Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci 98:4928-4940.
19. Huang P, Kehner GB, Cowan A, and Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695. (Pubitemid 32378001)
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
21. Jolliet-Riant P and Tillement JP (1999) Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol 13:16-26.
22. Kalvass JC, Olson ER, and Pollack GM (2007) Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metab Dispos 35:455-459. (Pubitemid 46333909)
23. Kamei J, Ohsawa M, and Nagase H (1996) Possible involvement of μ2-opioid receptor-mediated mechanisms in morphine-induced enhancement of the pentobarbital-induced loss of the righting reflex in the mouse. Life Sci 59:PL349-PL353.
24. Kharasch ED, Hoffer C, and Whittington D (2004) The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 57:600-610. (Pubitemid 38582180)
25. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294. (Pubitemid 28067324)
26. McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, et al. (2006) Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 43 (Suppl 4):S224-S234. (Pubitemid 44901890)
27. McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, and Rainey PM (2007) Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 91:269-278. (Pubitemid 47539730)
28. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, and Rainey PM (2011) Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 118:326-334.
29. Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED, and Gereau RW 4th (2009) The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J Pharmacol Exp Ther 330:834-843.
30. Moody DE, Chang Y, Huang W, and McCance-Katz EF (2009) The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol 105:211-215.
31. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, and Foltz RL (2002) A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 306:31-39. (Pubitemid 34722013)
32. Nath C, Gupta MB, Patnaik GK, and Dhawan KN (1994) Morphine-induced straub tail response: mediated by central μ2-opioid receptor. Eur J Pharmacol 263:203-205. (Pubitemid 24290273)
33. Nekhayeva IA, Nanovskaya TN, Hankins GD, and Ahmed MS (2006) Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-α-acetylmethadol, and paclitaxel. Am J Perinatol 23:423-430. (Pubitemid 44630804)
34. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, and Iga T (1997) Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281:428-433. (Pubitemid 27203097)
35. Ohtani M, Kotaki H, Sawada Y, and Iga T (1995) Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505-510.
36. Oka T, Liu XF, Kajita T, Ohgiya N, Ghoda K, Taniguchi T, Arai Y, and Matsumiya T (1992) Effects of the subcutaneous administration of enkephalins on tail-flick response and righting reflex of developing rats. Brain Res Dev Brain Res 69:271-276.
37. Pardridge WM (1997) Drug delivery to the brain. J Cereb Blood Flow Metab 17:713-731.
38. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, and Woolley JL (1999) Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212. (Pubitemid 29393608)
39. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
40. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514. (Pubitemid 40824964)
41. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, and Lötsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651-660. (Pubitemid 38316509)
42. Storch CH, Theile D, Lindenmaier H, Haefeli WE, and Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573-1581. (Pubitemid 46527547)
43. Thompson SJ, Koszdin K, and Bernards CM (2000) Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92:1392-1399. (Pubitemid 30257201)
44. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, and Declèves X (2010) Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 13:905-915.
45. Uhr M, Grauer MT, and Holsboer F (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54:840-846. (Pubitemid 37205136)
46. van Waterschoot RA and Schinkel AH (2011) A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev 63:390-410.
47. Walsh SL, Preston KL, Stitzer ML, Cone EJ, and Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580. (Pubitemid 24192243)
48. Wandel C, Kim R, Wood M, and Wood A (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-920. (Pubitemid 34266685)
49. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, and DeVane CL (2004) Brain penetration of methadone (R)-and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173:132-138. (Pubitemid 38591157)
50. Xie R, Hammarlund-Udenaes M, de Boer AG, and de Lange EC (1999) The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a(-/-) and mdr1a(+/+) mice. Br J Pharmacol 128:563-568. (Pubitemid 29504744)
51. Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, and Danhof M (2007) Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther 321:598-607. (Pubitemid 46624519)
52. Zacny JP, Conley K, and Galinkin J (1997) Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 282:1187-1197. (Pubitemid 27408294)
53. Zong J and Pollack GM (2000) Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm Res 17:749-753. (Pubitemid 30670642)